<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Protein S deficiency
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Protein S deficiency
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Protein S deficiency
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth A Bauer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein S deficiency is an inherited thrombophilia associated with an increased risk of thromboembolism. Establishing a diagnosis of hereditary protein S deficiency may be difficult, particularly in the setting of an acute thrombosis or anticoagulant administration.
        </p>
        <p>
         This topic review discusses the diagnosis and management of protein S deficiency.
        </p>
        <p>
         Separate topic reviews address the appropriate use of thrombophilia testing in various clinical settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children – (See
         <a class="medical medical_review" href="/z/d/html/5920.html" rel="external">
          "Thrombophilia testing in children and adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with venous thromboembolism – (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with stroke – (See
         <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">
          "Overview of the evaluation of stroke", section on 'Blood tests'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with pregnancy loss – (See
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy", section on 'Selection of patients for testing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic patients with a positive family history – (See
         <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">
          "Screening for inherited thrombophilia in asymptomatic adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3821518132">
         <span class="h2">
          Biology of protein S
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein S is named for
         <strong>
          S
         </strong>
         eattle, Washington, where it was originally discovered and purified. Protein S is a vitamin K-dependent glycoprotein, but it is not a zymogen of a serine protease enzyme. It serves as a cofactor for activated protein C, which inactivates procoagulant factors Va and VIIIa, reducing thrombin generation  (
         <a class="graphic graphic_figure graphicRef110320" href="/z/d/graphic/110320.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Protein S also serves as a cofactor for activated protein C in enhancing fibrinolysis and can directly inhibit prothrombin activation via interactions with other coagulation factors [
         <a href="#rid2">
          2-6
         </a>
         ].
        </p>
        <p>
         Protein S deficiency impairs this normal control mechanism, increasing the risk of thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Activated protein C and protein S'
         </a>
         .)
        </p>
        <p>
         Protein S is primarily synthesized by hepatocytes, but there is also evidence that it can be made in endothelial cells and megakaryocytes. It undergoes vitamin K-dependent gamma-carboxylation, which is required for its activity. (See
         <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">
          "Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"
         </a>
         .)
        </p>
        <p>
         Mature gamma-carboxylated protein S circulates in two states: free, and bound to the complement component C4b-binding protein (C4b-BP) [
         <a href="#rid7">
          7
         </a>
         ]. The free form comprises 30 to 40 percent of total protein S and is the only form of protein S that has cofactor activity for activated protein C [
         <a href="#rid7">
          7,8
         </a>
         ]. The average plasma concentration of total protein S in adults is 23 mcg/mL [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Total protein S levels change with age, but free protein S levels are more constant:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total protein S levels in healthy newborns at term are 15 to 30 percent of that in adults, while C4b-binding protein is markedly reduced to less than 20 percent. Thus, free protein S predominates and functional protein S levels are only slightly reduced compared with those in adults [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protein S levels increase with advancing age and are significantly lower and more variable in females than males [
         <a href="#rid11">
          11,12
         </a>
         ]. In women, the increase with age is seen with total protein S but not free protein S; a finding that has been explained by an increase in C4b-BP levels during normal aging [
         <a href="#rid11">
          11,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Free and total protein S levels appear to be higher in men than in women, although no clinical significance has been ascribed to this minor difference. In a series of 3788 healthy blood donors in Scotland, protein S levels in men were approximately 10 to 20 percent higher than in women [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Serum lipids may affect protein S levels. In one series of 150 adults in a community practice, total protein S levels were increased as much as 10 percent between those with the lowest versus the highest cholesterol levels, and free protein S rose as much as 30 percent between those with the lowest versus the highest triglyceride levels [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Genetics of protein S deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein S deficiency (MIM 612336) is an autosomal dominant condition due to mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F176880&amp;token=87jLzclRwWxNoI%2BQq5Gg77jKXbCVx1b1EpaDwUzCNPdyOF%2BlwOaMvkVZ38gg%2BnwX&amp;TOPIC_ID=1357" target="_blank">
          PROS1
         </a>
         gene, a large gene on chromosome 3. The first descriptions of familial protein S deficiency were reported in 1984 [
         <a href="#rid15">
          15-17
         </a>
         ]. Subsequently, a number of additional families and familial mutations have been described [
         <a href="#rid18">
          18-23
         </a>
         ].
        </p>
        <p>
         The majority of individuals with hereditary protein S deficiency are heterozygous for a
         <em>
          PROS1
         </em>
         mutation, although rare homozygous or compound heterozygous individuals with much more severe clinical features have been reported (see
         <a class="local">
          'Clinical features'
         </a>
         below). A pseudogene (noncoding gene),
         <em>
          PROS2
         </em>
         , is located on the same chromosome but does not appear to have any clinical relevance [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         The large size of the
         <em>
          PROS1
         </em>
         gene and the presence of the pseudogene have complicated the identification of mutations, although an increasing number are being reported. Mutations have been identified in 70 percent of protein S-deficient probands, and a database of known
         <em>
          PROS1
         </em>
         mutations has been published [
         <a href="#rid26">
          26,27
         </a>
         ]. Molecular analysis also has identified a few cases of large
         <em>
          PROS1
         </em>
         gene deletions [
         <a href="#rid26">
          26,28-30
         </a>
         ].
        </p>
        <p>
         Inherited protein S deficiency can be subdivided according to whether the abnormality affects total protein S antigen level, free protein S antigen level, and/or protein S function (activity) [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type I
         </strong>
         – Type I deficiency (reduced total protein S, free protein S, and protein S function) is the classic type of inherited protein S deficiency. Typical findings include total protein S of approximately 50 percent of normal and free protein S as low as 15 percent of normal [
         <a href="#rid15">
          15,19
         </a>
         ]. Most of the mutations responsible for type I deficiency are missense or nonsense mutations [
         <a href="#rid31">
          31
         </a>
         ]. Microinsertions, microdeletions, and splice site mutations have also been reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type II
         </strong>
         – Type II deficiency (normal total and free protein S; reduced protein S function) is rare (case reports only). This is also referred to as a qualitative defect. Five mutations described in the original reports were missense mutations located in the aminoterminal end of the protein, which includes the domains that interact with activated protein C [
         <a href="#rid32">
          32-35
         </a>
         ]. These mutations may alter the conformation of protein S or interfere with carboxylation of the gamma-carboxyglutamic acid domain of the protein [
         <a href="#rid33">
          33
         </a>
         ]. In a series of 118 French patients with thromboembolism associated with protein S deficiency, 26 had a serine to proline substitution at amino acid 460 (the Heerlen polymorphism), which affects protein S metabolism [
         <a href="#rid36">
          36,37
         </a>
         ]. The low free plasma protein S may result from increased binding of the abnormal protein S to C4b-binding protein [
         <a href="#rid38">
          38,39
         </a>
         ]. The thrombophilic risk with this polymorphism has been questioned [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type III
         </strong>
         – Type III deficiency (selectively reduced free protein S and protein S function; normal total protein S) is another type of quantitative defect.
        </p>
        <p>
        </p>
        <p>
         In some families, different individuals have either type I or type III protein S deficiency, suggesting that the same mutation can cause different laboratory patterns [
         <a href="#rid11">
          11,40-42
         </a>
         ].
        </p>
        <p>
         Distinction among types is important for research purposes but does not affect disease severity or clinical management [
         <a href="#rid43">
          43
         </a>
         ]. In the Protein S Deficiency Database, patient phenotypes are described as quantitative (types I or III) or qualitative (type II) [
         <a href="#rid27">
          27
         </a>
         ]. Additional information on these mutations and their associated thrombotic risks can be obtained from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.isth.org%2F&amp;token=AxdOYZDP6%2F9e17f8kv7xV1qkorJXE3HRE02%2BTlOR6ds%3D&amp;TOPIC_ID=1357" target="_blank">
          International Society on Thrombosis and Haemostasis (ISTH)
         </a>
         .
        </p>
        <p class="headingAnchor" id="H10173160">
         <span class="h2">
          Causes of reduced protein S
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to
         <em>
          PROS1
         </em>
         gene mutations (see
         <a class="local">
          'Genetics of protein S deficiency'
         </a>
         above), reduced protein S levels have been seen in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/429.html" rel="external">
          "Maternal adaptations to pregnancy: Hematologic changes", section on 'Coagulation and fibrinolysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral hormonal contraceptive use [
         <a href="#rid12">
          12,45
         </a>
         ]. However, menopausal hormone therapy does not appear to alter protein S levels [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disseminated intravascular coagulation [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute thrombosis  (
         <a class="graphic graphic_table graphicRef76966" href="/z/d/graphic/76966.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human immunodeficiency virus (HIV) infection (significantly reduced total and free protein S) [
         <a href="#rid49">
          49
         </a>
         ]. A correlation with increased thromboembolism risk has not been established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nephrotic syndrome (typically characterized by increased total protein S levels but reduced protein S function) [
         <a href="#rid50">
          50,51
         </a>
         ]. This pattern is in part due to urinary loss of free protein S and elevated plasma C4b-binding protein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease (moderate decrease in total and free protein S) [
         <a href="#rid38">
          38,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         L-asparaginase chemotherapy [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a boy recovering from chickenpox (varicella-zoster virus infection) transient isolated deficiency of protein S induced by an autoantibody directed against protein S was associated with renal and spermatic vein thrombosis [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         C4b-binding protein is an acute phase reactant. Thus, several of the conditions listed above may be associated with a shift of protein S from the free form to the bound (inactive) form, potentially leading to an erroneous diagnosis of protein S deficiency [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants"
         </a>
         and
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         The clinical implications of these protein S reductions may differ from inherited protein S deficiency; some of these conditions are associated with multiple coagulation factor deficiencies, making it difficult to establish whether the increased risk of thrombosis is attributable to protein S deficiency or to the combination of abnormalities.
        </p>
        <p class="headingAnchor" id="H10172658">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of hereditary protein S deficiency has been challenging to establish due to the variability of protein S levels among different individuals, the use of different tests that may measure different pools of protein S, and the lack of a clear threshold below which protein S deficiency can be diagnosed reliably  (
         <a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Choice and interpretation of protein S assay'
         </a>
         below.)
        </p>
        <p>
         Data from the 2013 MEGA study (Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis) suggest that protein S deficiency may be much less common than previously thought [
         <a href="#rid54">
          54
         </a>
         ]. As noted below (see
         <a class="local">
          'Venous thromboembolism'
         </a>
         below), the individuals in this series included 2331 adults with a personal history of venous thromboembolism (VTE) without a strong family history and 2872 controls. When protein S deficiency was defined by the level of free protein S that correlated with an increased likelihood of VTE (&lt;33 units/dL), the frequency of protein S deficiency in this population was quite low (approximately 48 of 5317; 0.9 percent). Only 10 of these individuals had a
         <em>
          PROS1
         </em>
         mutation. Earlier studies had reported frequencies of protein S deficiency in the range of 2 to 8 percent among individuals with VTE [
         <a href="#rid18">
          18,20,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Venous thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Venous thromboembolism (VTE) including deep vein thrombosis and pulmonary embolism is the major clinical manifestation of protein S deficiency.
        </p>
        <p>
         The absolute risk of VTE, typical age of presentation, and recurrence risk varies depending on the study population, with greater risks and younger age of presentation typically seen in thrombophilic families and individuals with combined inherited or inherited plus acquired VTE risk factors. Hereditary protein S deficiency is a rare risk factor for VTE in the absence of a family history. Available studies involving thrombophilic families and the general population include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 30 children with protein S deficiency who presented with VTE, the median age of the first thromboembolic event was 14.5 years [
         <a href="#rid55">
          55
         </a>
         ]. There was an additional thrombophilic risk factor in 18 (60 percent) of the children, such as oral contraceptive use, chemotherapy, or prolonged immobilization. The remaining 12 events (40 percent) were unprovoked. Sites of thrombosis were deep veins of the leg (DVT; 12 events; 40 percent), cerebral veins (8 events; 27 percent), DVT and pulmonary embolism (PE; 5 events; 17 percent), calf vein (3 events; 10 percent), intracardiac veins (1 event), and purpura fulminans (1 event). There was a positive family history of thrombophilia in 17 (57 percent). As noted above, these 30 children represented 8 percent of children referred to the center for VTE. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series involving 12 thrombophilic families, 71 of 136 individuals tested (52 percent) had protein S deficiency, consistent with autosomal dominant transmission [
         <a href="#rid22">
          22
         </a>
         ]. Of these, 39 (55 percent) had VTE. Most were DVT or PE, although there were five in unusual sites (eg, mesenteric or cerebral veins). The mean age of first thrombotic event was 28 years (range, 15 to 68 years). Approximately one-half the events were spontaneous and one-half were considered to be provoked.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2013 meta-analysis of studies involving patients with portal vein thrombosis (PVT) or hepatic vein thrombosis (Budd-Chiari syndrome [BCS]), inherited protein S deficiency was found in 3 percent of each group [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a general population of individuals with a first VTE but without a strong family history of thrombophilia, the risk of VTE attributed to protein S deficiency appears to be lower than that in thrombophilic families.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) case control study compared protein S levels in 4956 individuals with a first episode of VTE and 6297 controls (partners of patients or individuals identified by random digit telephone calls) [
         <a href="#rid54">
          54
         </a>
         ]. Protein S levels below the 2.5
         <sup>
          th
         </sup>
         percentile (&lt;53 units/dL for free protein S; &lt;68 units/dL for total protein S), did not correlate with an increased risk of VTE (eg, odds ratio [OR] for free protein S 0.82, 95% CI 0.56-1.21). Only when the cutoff was set at a free protein S level below the 0.1
         <sup>
          th
         </sup>
         percentile (ie, levels in the bottom one-tenth of one percent; &lt;33 units/dL) did the odds of VTE increase, although this did not reach statistical significance (OR 5.44, 95% CI 0.6-48.8). Total protein S levels did not correlate with thrombosis, even below the 0.1
         <sup>
          th
         </sup>
         percentile. As noted above, the clinical implications of MEGA are that hereditary protein S deficiency is a rare risk factor for VTE if testing is carried out in the absence of a family history.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some individuals with protein S deficiency and VTE also have a second thrombophilic defect. This was illustrated in a series of families with protein S deficiency, in which slightly over a third of families also had the factor V Leiden (FVL) mutation [
         <a href="#rid57">
          57
         </a>
         ]. The risk of VTE was greater in those with both defects (13 of 18 [72 percent]; versus 4 of 21 with protein S deficiency alone and 4 of 21 with FVL mutation alone). Similar findings of increased VTE risk in individuals with combined protein S deficiency and FVL mutation have been reported by others [
         <a href="#rid36">
          36,58,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to DVT and PE, thrombosis has also been reported in the axillary, mesenteric, and cerebral veins in patients with protein S deficiency.
        </p>
        <p>
         Complications typically associated with protein C deficiency such as purpura fulminans and warfarin-induced skin necrosis have also been described with protein S deficiency [
         <a href="#rid55">
          55,60
         </a>
         ]. (See
         <a class="local">
          'Neonatal purpura fulminans'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Warfarin-induced skin necrosis'
         </a>
         .)
        </p>
        <p>
         Our approach to deciding which patients with VTE should be tested for inherited thrombophilias is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Arterial thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several case reports have described young patients with arterial thrombosis in the setting of inherited protein S deficiency [
         <a href="#rid61">
          61-63
         </a>
         ]. However, larger studies have not convincingly demonstrated that protein S deficiency is a risk factor for arterial thrombosis [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p>
         Examples of available data include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein S deficiency in patients with stroke
         </strong>
         – In a series of 127 consecutive patients admitted for an acute ischemic stroke, abnormally low levels of protein S were found in four (3 percent) [
         <a href="#rid65">
          65
         </a>
         ]. Three were attributed to pregnancy and not to an inherited defect; the finding of protein S deficiency did not alter patient management in any case. In another series of 120 patients with cerebral ischemic events, 20 (17 percent) had decreased protein S levels, but on repeat testing protein S levels were only low in two (2 percent) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial thrombosis in patients with protein S deficiency
         </strong>
         – In a cohort of 3052 healthy men ages 49 to 64, a reduced free protein S level was not associated with an increased risk of stroke; however, it was associated with a modest increase in coronary artery disease (hazard ratio [HR] 1.85, 95% CI 1.1-3.2) [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Our approach to deciding which individuals with stroke should be tested for inherited thrombophilias is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">
          "Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Hypercoagulable evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">
          "Overview of the evaluation of stroke", section on 'Blood tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6037711">
         <span class="h2">
          Neonatal purpura fulminans
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe thrombotic complications, including neonatal purpura fulminans, have been reported in newborns with very low protein S levels; this is rare and typically due to homozygous deficiency [
         <a href="#rid68">
          68,69
         </a>
         ]. An animal model of complete absence of protein S demonstrated late embryonic death due to intracerebral thrombosis and hemorrhage, as well as abnormal blood vessel development [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1353849683">
         <span class="h2">
          Obstetrical complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are mixed regarding the role of protein S deficiency in miscarriage. The increased risk, if any, is small. (See
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy"
         </a>
         .)
        </p>
        <p>
         As noted above, however, pregnancy and the postpartum period increase the risk of maternal VTE over and above that attributable to protein S deficiency. (See
         <a class="local">
          'Venous thromboembolism'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H11881590">
         <span class="h2">
          Overview of evaluation and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other inherited thrombophilias, protein S deficiency may be suspected in an individual with venous thromboembolism (VTE) in association with one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Strong family history of VTE
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known familial protein S deficiency
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First VTE event before age 50
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VTE in an unusual site such as portal, mesenteric, or cerebral vein
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent VTE
        </p>
        <p>
        </p>
        <p>
         For some individuals such as those with recurrent or life-threatening VTE for whom indefinite anticoagulation is indicated, the diagnosis of protein S deficiency may not alter management. However, there may be a role for identifying a familial defect to allow testing and counseling of first-degree relatives such as women considering the use of hormonal contraceptives, or individuals who would benefit from additional counseling and/or interventions to reduce VTE risk. (See
         <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">
          "Screening for inherited thrombophilia in asymptomatic adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias"
         </a>
         .)
        </p>
        <p>
         Unless the specific familial defect is known, individuals with VTE who warrant testing should be evaluated for other inherited thrombophilias and in some cases for acquired thrombophilias such as antiphospholipid syndrome (especially if the activated partial thromboplastin time [aPTT] is prolonged) or a myeloproliferative neoplasm (if there is erythrocytosis or thrombocytosis). (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p>
         In contrast, we generally do not perform routine testing for protein S deficiency in the setting of VTE that is provoked or occurs in an individual over 50 years of age in the absence of a positive family history of VTE.
        </p>
        <p>
         Once a decision is made to pursue testing, choosing the appropriate assay and criteria for diagnosis are challenging. (See
         <a class="local">
          'Choice and interpretation of protein S assay'
         </a>
         below.)
        </p>
        <p>
         Additional information regarding the role of thrombophilia testing in specific clinical settings is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portal vein thrombosis – (See
         <a class="medical medical_review" href="/z/d/html/88016.html" rel="external">
          "Epidemiology and pathogenesis of portal vein thrombosis in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stroke – (See
         <a class="medical medical_review" href="/z/d/html/1089.html" rel="external">
          "Stroke: Etiology, classification, and epidemiology", section on 'Blood disorders'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children – (See
         <a class="medical medical_review" href="/z/d/html/5920.html" rel="external">
          "Thrombophilia testing in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4226152226">
         <span class="h2">
          Choice and interpretation of protein S assay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein S deficiency is the most difficult of the hereditary thrombophilias to document with certainty. As previously noted, protein S levels in the general population vary more widely than those of protein C or antithrombin. (See
         <a class="local">
          'Biology of protein S'
         </a>
         above.)
        </p>
        <p>
         Free protein S is our preferred approach to screening as it appears to be the best test for true deficiency [
         <a href="#rid72">
          72,73
         </a>
         ]. Combining free protein S levels with other testing such as a functional assay does not appear to improve diagnostic accuracy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Free protein S
         </strong>
         – Free protein S level is measured using an immunoassay. Various monoclonal antibody-based or ligand-based (eg, C4b-binding protein) detection methods are available [
         <a href="#rid31">
          31,74-76
         </a>
         ]. Earlier assays used polyethylene glycol precipitation to remove protein S bound to C4b-binding protein [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Total protein S
         </strong>
         – Total protein S level is measured using an immunoassay. Polyclonal antibody-based methods are often used [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein S functional assay
         </strong>
         – Protein S function is measured in a coagulation-based assay in which the time to clot formation is proportional to the plasma protein S activity [
         <a href="#rid78">
          78,79
         </a>
         ]. One problem with the functional protein S assay is the large coefficient of variation. Another problem is that some of these assays are also sensitive to the defect characterized by resistance to activated protein C (aPC) such as seen in individuals with the factor V Leiden (FVL) mutation. As a result, their use can lead to an erroneous diagnosis of functional protein S deficiency in a patient who has another cause of aPC resistance [
         <a href="#rid80">
          80
         </a>
         ]. A strategy of first screening plasma samples for aPC resistance prior to performing a functional protein S assay can obviate this potential problem. As noted above, however, measurement of free protein S level is our preferred approach.
        </p>
        <p>
        </p>
        <p>
         There is no ideal cutoff level that distinguishes between individuals with and without protein S deficiency. The value used depends on the assay, the clinical setting, and the age of the patient:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a strong family history of VTE, only those with a free protein S antigen level of &lt;41 international units/dL were at increased risk for a first episode of venous thrombosis [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who are asymptomatic or who have a first VTE in the absence of a strong family history, lower levels of free protein S (eg, &lt;33 units/dL) are more predictive for an increased risk of VTE [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For newborns, it is important to use age-based norms for the specific laboratory performing the test, as these may differ from normal adult values, especially for total protein S levels. (See
         <a class="local">
          'Biology of protein S'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         For most patients it is necessary to perform repeat testing and take into account the family history of thrombosis when making the diagnosis, regardless of which test is used.
        </p>
        <p>
         In contrast to these plasma-based tests, genetic testing for protein S deficiency is neither feasible nor readily available outside of a research setting.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Timing of testing and effect of anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of thrombophilia testing relative to a VTE event and/or anticoagulation administration is an important consideration in laboratory testing for suspected protein S deficiency (as is also the case for suspected deficiency of antithrombin [AT] or protein C).
         <span class="utd-adt-cnt utd-adt-labi">
          (Related Lab Interpretation Monograph(s):
          <a class="narrative narrative_labi" href="/contents/low-protein-s-in-adults?topicRef=1357&amp;source=see_link">
           "Low protein S in adults"
          </a>
          .)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease, acute thrombosis, pregnancy, and any comorbid illness that causes an acute phase response can lower the level of free protein S, resulting in erroneous diagnosis of protein S deficiency. (See
         <a class="local">
          'Causes of reduced protein S'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin K antagonists can cause reduced protein S levels. A finding of a normal protein S level in the setting of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         therapy excludes protein S deficiency; however, a low protein S level in the setting of warfarin therapy must be repeated when the individual is no longer receiving a vitamin K antagonist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In practice, it is preferable to investigate patients suspected of having protein S (or protein C) deficiency after a vitamin K antagonist has been discontinued for at least two weeks. If it is not possible to discontinue
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         due to the severity of the thrombosis or thrombotic risk, it may be possible to assay protein S levels while the patient is receiving heparin, which does not alter protein S concentration. Another option that was proposed in the setting of vitamin K antagonist therapy many years ago is to measure the ratio of protein S to prothrombin or other vitamin K-dependent coagulation factor, and to infer a diagnosis of protein S deficiency if this ratio is low; however, this method has not been validated [
         <a href="#rid15">
          15,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct oral anticoagulants (DOACs;
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ) can affect the functional assays for protein S (which use a clotting endpoint) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heparin and low molecular weight heparin do not interfere with testing for protein S deficiency [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2272193991">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of VTE includes other inherited thrombophilias and acquired risk factors for thrombosis. For individuals without clinical findings, a borderline protein S value may simply represent a level below the lower limit of the normal range, which is established in such a way that a small percentage of unaffected individuals will have a level below "normal."
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other inherited thrombophilias
         </strong>
         – Other inherited thrombophilias include factor V Leiden (FVL) mutation, protein C deficiency, antithrombin (AT) deficiency, and prothrombin G20210A mutation; of these, FVL is the most common. Like protein S deficiency, patients may present with a positive personal or family history of VTE or other thromboembolic complications. Unlike protein S deficiency, individuals with these other inherited thrombophilias will have laboratory evidence of the other specific defect and will have normal protein S levels, unless tested in the setting of acute illness, thrombosis, or interfering anticoagulant. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired VTE risk factors
         </strong>
         – A number of acquired risk factors for VTE have been described, including immobility, surgery, trauma, cancer or myeloproliferative neoplasms (MPN), certain drugs, the antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria (PNH), disseminated intravascular coagulation (DIC), and hormonal changes including hormonal contraceptives, pregnancy, and the postpartum period. Like protein S deficiency, these patients may have VTE in typical or atypical locations. Unlike protein S deficiency, these acquired risk factors are often obvious from the patient's history and/or laboratory studies; the family history typically does not reveal thrombophilia in these acquired disorders. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis", section on 'Acquired risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10173499">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2927060067">
         <span class="h2">
          Patients with VTE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management of acute venous thromboembolism (VTE) in patients with inherited protein S deficiency is not different from that in patients without an inherited thrombophilia and typically includes anticoagulation for at least three to six months  (
         <a class="graphic graphic_algorithm graphicRef107766" href="/z/d/graphic/107766.html" rel="external">
          algorithm 1
         </a>
         ). Protein S deficiency does not alter the choice of anticoagulant or dosing, which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
         The choice between a direct oral anticoagulant (DOAC) versus
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is based on a number of factors including the severity of thrombosis, patient preference, adherence to therapy, and potential drug and dietary interactions. We are more likely to use a DOAC for individuals with typical VTE presentations and more likely to use warfarin for individuals with extremely high or low body weights, concerns about adherence, or a potential benefit from maintaining an INR in the high end of the therapeutic range (eg, those with a submassive or massive pulmonary embolism [PE] with severe clinical presentations such as hypoxemia/shock or those with deep vein thrombosis [DVT] with proximal clot burden).
        </p>
        <p>
         The decision to continue anticoagulation beyond three to six months or indefinitely depends on whether the thrombosis was provoked or unprovoked and other factors. Indefinite anticoagulation is recommended for many patients with an unprovoked thromboembolic event, regardless of whether an inherited thrombophilia is identified; the documentation of protein S deficiency may strengthen the case for indefinite anticoagulation, particularly if there is a strong family history of VTE. Other factors that make us more likely to advise indefinite anticoagulation include recurrent thrombosis, life-threatening thrombosis, thrombosis at an unusual site, or more than one inherited prothrombotic defect. These issues are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
         If it is decided to use a DOAC for the long-term prevention of recurrent VTE, we generally continue a higher dose regimen (eg,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         20 mg once daily or
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         5 mg twice daily rather than rivaroxaban 10 mg once daily or apixaban 2.5 mg twice daily), assuming the individual's bleeding risk is not excessive. This is because protein S deficiency is one of the more thrombophilic of the hereditary thrombophilias. The prescribing physician and patient should understand that evidence for the optimal dose in such patients is lacking.
        </p>
        <p class="headingAnchor" id="H157654913">
         <span class="h2">
          Asymptomatic individuals (obstetrical/surgical prophylaxis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with protein S deficiency who have not had a thromboembolic event are not treated with routine anticoagulation. (See
         <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">
          "Screening for inherited thrombophilia in asymptomatic adults"
         </a>
         .)
        </p>
        <p>
         We generally avoid oral contraceptives in women with inherited protein S deficiency. However, there may be settings in which an individual with protein S deficiency may be treated with oral contraceptives if this is in the best interest of the patient based on the judgment of the treating clinician. An example would be a patient who strongly wishes to avoid pregnancy and cannot or will not use another method of birth control, especially if the family history of thrombosis is absent or weak. A comprehensive discussion of contraceptive counseling that addresses other scenarios is presented separately (see
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias"
         </a>
         ). We also provide education regarding conditions that increase thrombotic risk (eg, prolonged immobility).
        </p>
        <p>
         Individuals with protein S deficiency may also benefit from the judicious use of prophylactic anticoagulation in certain settings, especially if they have a strong family history of thrombophilia or other VTE risk factors  (
         <a class="graphic graphic_algorithm graphicRef107766" href="/z/d/graphic/107766.html" rel="external">
          algorithm 1
         </a>
         ). The greatest benefit is likely to be seen in those at greatest risk of VTE such as those with a strong family history of thrombophilia or surgery/pregnancy associated with prolonged immobility; benefit may be lower (or absent) in those with less VTE risk such as those with an absent or weak family history of thrombosis and a briefer period of immobility. Recommendations for anticoagulation in specific settings are presented in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute medical illness
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H251392983">
         <span class="h2">
          Testing of first-degree relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         The testing of asymptomatic first-degree relatives can be delayed until after puberty and is generally most helpful in settings in which the risk of thrombosis is increased, such as initiation of oral hormonal contraceptives or pregnancy. This subject is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">
          "Screening for inherited thrombophilia in asymptomatic adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3922427764">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26779752">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein S function
         </strong>
         – Protein S (for Seattle) is a negative regulator of coagulation. It circulates free and bound to C4b-binding protein; only the free form is active. Free protein S is a cofactor for protein C, which inactivates procoagulant factors Va and VIIIa  (
         <a class="graphic graphic_figure graphicRef110320" href="/z/d/graphic/110320.html" rel="external">
          figure 1
         </a>
         ). Protein S deficiency is autosomal dominant; most individuals are heterozygous for a
         <em>
          PROS1
         </em>
         mutation. Reduced protein S occurs in several acquired conditions for which its clinical significance is unclear. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – The prevalence of hereditary protein S deficiency has been difficult to establish and may be &lt;1 percent of individuals with venous thromboembolism (VTE). (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VTE risk
         </strong>
         – Protein S deficiency increases VTE risk. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are most common, but thrombosis also occurs in other sites (cerebral and mesenteric vein). Younger age of presentation is typically seen in thrombophilic families and individuals with combined VTE risk factors. Data are limited regarding risks of arterial thrombosis and obstetric complications. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Protein S deficiency may be suspected in an individual with a strong family history of thrombophilia or known familial protein S deficiency, first VTE before age 50, VTE in an unusual site, or recurrent VTE. For some individuals, the diagnosis of protein S deficiency may not alter management. There may be a role for identifying this disorder to allow testing and counseling of first-degree relatives (especially females) considering estrogen-containing contraceptives. (See
         <a class="local">
          'Overview of evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Protein S deficiency is difficult to document with certainty. Free protein S (measured by immunoassay) is probably the best screening test. The cutoff value depends on the assay, clinical setting, and patient age. For most patients, it is necessary to repeat testing and incorporate family history of thrombophilia when making the diagnosis. An erroneous diagnosis can be made with acute VTE or during pregnancy certain illnesses, or treatment with certain anticoagulants, especially vitamin K antagonists  (
         <a class="graphic graphic_table graphicRef76966" href="/z/d/graphic/76966.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Choice and interpretation of protein S assay'
         </a>
         above and
         <a class="local">
          'Timing of testing and effect of anticoagulants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VTE treatment
         </strong>
         – Acute VTE management is not different from VTE in the general population and typically includes anticoagulation for at least three to six months  (
         <a class="graphic graphic_algorithm graphicRef107766" href="/z/d/graphic/107766.html" rel="external">
          algorithm 1
         </a>
         ). Extended anticoagulation beyond three to six months depends on whether the thrombosis was provoked or unprovoked and other factors. Documented protein S deficiency may strengthen the case for indefinite anticoagulation, particularly if there is a strong family history of VTE. (See
         <a class="local">
          'Patients with VTE'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VTE prevention
         </strong>
         – We generally avoid oral contraceptives in women with inherited protein S deficiency, with rare exceptions. Individuals with protein S deficiency may also benefit from the judicious use of prophylactic anticoagulation in certain settings such as pregnancy or hospitalization, especially if they have a strong family history of thrombophilia or other VTE risk factors  (
         <a class="graphic graphic_algorithm graphicRef107766" href="/z/d/graphic/107766.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Asymptomatic individuals (obstetrical/surgical prophylaxis)'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">
          "Inherited thrombophilias in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General thrombophilia approach
         </strong>
         – Our approach to screening for inherited thrombophilia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">
          "Screening for inherited thrombophilia in asymptomatic adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5920.html" rel="external">
          "Thrombophilia testing in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H602918860">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges extensive contributions of Donald H Mahoney, Jr, MD, to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Esmon CT. Protein S and protein C Biochemistry, physiology, and clinical manifestation of deficiencies. Trends Cardiovasc Med 1992; 2:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hackeng TM, van 't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269:21051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenen RR, Tans G, van Oerle R, et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol 2008; 143:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahlbäck B. C4b-binding protein: a forgotten factor in thrombosis and hemostasis. Semin Thromb Hemost 2011; 37:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fair DS, Revak DJ. Quantitation of human protein S in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Thromb Res 1984; 36:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz HP, Muntean W, Watzke H, et al. Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood 1988; 71:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds RE, Zöller B, Ireland H, et al. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89:4364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boerger LM, Morris PC, Thurnau GR, et al. Oral contraceptives and gender affect protein S status. Blood 1987; 69:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykes AC, Walker ID, McMahon AD, et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacCallum PK, Cooper JA, Martin J, et al. Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998; 102:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz HP, Fischer M, Hopmeier P, et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broekmans AW, Bertina RM, Reinalda-Poot J, et al. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost 1985; 53:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heijboer H, Brandjes DP, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabernero MD, Tomas JF, Alberca I, et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engesser L, Broekmans AW, Briët E, et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ploos van Amstel JK, van der Zanden AL, Bakker E, et al. Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost 1987; 58:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidel DK, Tatro AV, Phelps LG, et al. Organization of the human protein S genes. Biochemistry 1990; 29:7845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost 1997; 78:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost 2000; 84:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ploos van Amstel HK, Huisman MV, Reitsma PH, et al. Partial protein S gene deletion in a family with hereditary thrombophilia. Blood 1989; 73:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidel DK, Nelson RM, Broxson EH Jr, et al. A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families. Blood 1991; 77:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes ZR, Bertina RM, Reitsma PH. Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Br J Haematol 1996; 92:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amiral J, Grosley B, Boyer-Neumann C, et al. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis 1994; 5:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gandrille S, Borgel D, Eschwege-Gufflet V, et al. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds RE, Ireland H, Kunz G, Lane DA. Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group. Blood 1996; 88:4195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigekiyo T, Uno Y, Kawauchi S, et al. Protein S Tokushima: an abnormal protein S found in a Japanese family with thrombosis. Thromb Haemost 1993; 70:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi T, Nishioka J, Shigekiyo T, et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994; 83:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgel D, Duchemin J, Alhenc-Gelas M, et al. Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies. J Lab Clin Med 1996; 128:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertina RM, Ploos van Amstel HK, van Wijngaarden A, et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duchemin J, Gandrille S, Borgel D, et al. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Blood 1995; 86:3436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zöller B, García de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85:3524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouwer JL, Veeger NJ, van der Schaaf W, et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen BD, Bisgaard ML, Lind B, et al. Characterization and structural impact of five novel PROS1 mutations in eleven protein S-deficient families. Thromb Haemost 2001; 86:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011; 86:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilabert J, Fernandez JA, España F, et al. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeb MJ, Mosher D, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989; 73:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988; 81:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmon CT, Vigano-D'Angelo S, D'Angelo A, Comp PC. Anticoagulation proteins C and S. Adv Exp Med Biol 1987; 214:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81:1801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigano-D'Angelo S, D'Angelo A, Kaufman CE Jr, et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987; 107:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gouault-Heilmann M, Gadelha-Parente T, Levent M, et al. Total and free protein S in nephrotic syndrome. Thromb Res 1988; 49:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pui CH, Chesney CM, Bergum PW, et al. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol 1986; 64:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo A, Della Valle P, Crippa L, et al. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pintao MC, Ribeiro DD, Bezemer ID, et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 2013; 122:3210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klostermeier UC, Limperger V, Kenet G, et al. Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study. Thromb Haemost 2015; 113:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol 2013; 28:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998; 28:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coller BS, Owen J, Jesty J, et al. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girolami A, Simioni P, Lazzaro AR, Cordiano I. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemost 1989; 61:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology 1992; 42:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allaart CF, Aronson DC, Ruys T, et al. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ken-Dror G, Cooper JA, Humphries SE, et al. Free protein S level as a risk factor for coronary heart disease and stroke in a prospective cohort study of healthy United Kingdom men. Am J Epidemiol 2011; 174:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez E, Ledford MR, Pegelow CH, et al. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994; 71:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009; 114:2307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009; 119:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds RE, Ireland H, Lane DA, et al. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smock KJ, Plumhoff EA, Meijer P, et al. Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories. Thromb Haemost 2016; 116:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardiner C, Mackie IJ, Machin SJ. Simultaneous assay of free and total protein S by ELISA using monoclonal and polyclonal antibodies. Clin Lab Haematol 1998; 20:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravanat C, Wiesel ML, Schuhler S, et al. One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis. Blood Coagul Fibrinolysis 1998; 9:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giri TK, Hillarp A, Härdig Y, et al. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertina RM, van Wijngaarden A, Reinalda-Poot J, et al. Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost 1985; 53:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf M, Boyer-Neumann C, Martinoli JL, et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989; 62:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preda L, Tripodi A, Valsecchi C, et al. A prothrombin time-based functional assay of protein S. Thromb Res 1990; 60:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faioni EM, Franchi F, Asti D, et al. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lijfering WM, Mulder R, ten Kate MK, et al. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 2009; 113:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson NV, Khor B, Van Cott EM. Advances in laboratory testing for thrombophilia. Am J Hematol 2012; 87 Suppl 1:S108.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1357 Version 42.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239244" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Protein S and protein C Biochemistry, physiology, and clinical manifestation of deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7701473" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The protein C anticoagulant system: inherited defects as basis for venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7620160" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8063724" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12730108" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759761" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21805441" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : C4b-binding protein: a forgotten factor in thrombosis and hemostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12907438" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6241357" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Quantitation of human protein S in the plasma of normal and warfarin-treated individuals by radioimmunoassay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2964259" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192759" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2948582" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Oral contraceptives and gender affect protein S status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380449" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9695981" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Associations of protein C and protein S with serum lipid concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6238642" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Plasma protein S deficiency in familial thrombotic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6239877" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Familial protein S deficiency is associated with recurrent thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6239102" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Recurrent venous thromboembolism in patients with a partial deficiency of protein S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9065991" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3161207" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2146503" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1826407" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2952034" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hereditary protein S deficiency: clinical manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746774" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2895503" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Two genes homologous with human protein S cDNA are located on chromosome 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2148110" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Organization of the human protein S genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9198178" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Protein S deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11127877" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Protein S deficiency: a database of mutations--summary of the first update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2521801" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Partial protein S gene deletion in a family with hereditary thrombophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1671337" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8616098" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7519888" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7803790" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8943854" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8236127" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Protein S Tokushima: an abnormal protein S found in a Japanese family with thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8298131" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8765219" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2143091" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2935211" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An abnormal plasma distribution of protein S occurs in functional protein S deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579448" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780139" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725093" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11776305" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Characterization and structural impact of five novel PROS1 mutations in eleven protein S-deficient families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21523802" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Protein S abnormalities: a diagnostic nightmare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2944555" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Functional and immunologic protein S levels are decreased during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2966452" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2521800" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3284913" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2959034" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Anticoagulation proteins C and S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8461466" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Protein S deficiency in men with long-term human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2954500" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Protein S deficiency occurs in the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2964743" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Total and free protein S in nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2946315" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497285" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24014240" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25272994" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23216127" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780138" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241710" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Familial thrombophilia: a complex genetic disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9607123" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9885367" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2960305" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2526383" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1533705" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Protein S deficiency in middle-aged women with stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2148653" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hereditary protein S deficiency in young adults with arterial occlusive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9724011" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9457624" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Coagulation disorders in young adults with acute cerebral ischaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21911828" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Free protein S level as a risk factor for coronary heart disease and stroke in a prospective cohort study of healthy United Kingdom men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1967377" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neonatal purpura fulminans associated with homozygous protein S deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7974339" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567881" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Generation and phenotypic analysis of protein S-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729839" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9424998" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27075008" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9681209" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Simultaneous assay of free and total protein S by ELISA using monoclonal and polyclonal antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9690804" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9569190" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3161206" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Determination of plasma protein S--the protein cofactor of activated protein C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2533413" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A new functional assay for human protein S activity using activated factor V as substrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2148988" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A prothrombin time-based functional assay of protein S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8165605" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18945960" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22473489" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Advances in laboratory testing for thrombophilia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
